Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms. (2022)
Attributed to:
nCoV: Developing CoV-bnMABs for therapy of highly pathogenic coronaviruses including SARS-CoV-2
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/vaccines11010058
PubMed Identifier: 36679903
Publication URI: http://europepmc.org/abstract/MED/36679903
Type: Journal Article/Review
Volume: 11
Parent Publication: Vaccines
Issue: 1
ISSN: 2076-393X